Why the study?
To generate an induced pluripotent stem cell line to allow further assessment of the pathophysiological development of hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
The generation of this patient-specific iPSC line provides a valuable resource for studying the pathophysiological mechanisms of hypertrophic cardiomyopathy caused by the MYH7 p.Arg403Gln mutation.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy characterized by left ventricular hypertrophy ≥15 mm in the absence of loading conditions. HCM has a prevalence of up to one in 200, and can result in significant adverse outcomes including heart failure and sudden cardiac death. An induced pluripotent stem cell (iPSC) line was generated from peripheral blood mononuclear cells obtained from the whole blood of a 38-year-old female patient with HCM in which genetic testing identified the well-known pathogenic p.Arg403Gln mutation in myosin heavy chain 7. iPSCs express pluripotency markers, demonstrate trilineage differentiation capacity, and display a normal 46,XX female karyotype. This resource will allow further assessment of the pathophysiological development of HCM.
No takes yet. Share an insight, caveat, or question.
Holliday et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: